Quarterly Activities/Appendix 4C Cash Flow Report - Amended
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The report details the initiation of a pilot clinical study for Libbo, a treatment for erectile dysfunction, and the achievement of a solubility milestone for apixaban using proprietary technology. Additionally, Ben Rohr has been appointed as the new Chief Executive Officer to enhance the company's focus on commercial execution and growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EVE Health Group Limited on 6ix
Story so far
Earlier from EVE Health
- Eve Initiates Pilot Clinical Study for Libbo ED Film
- Appointment of Chief Executive Officer
- Investor Presentation
- Prospectus
- EVE Placement Update
Later from EVE Health
All EVE Health news releasesFollow EVE Health into a list and get an email when it puts out news.
Follow EVE Health